The following table or figure may be downloaded to PowerPoint for personal use in teaching and presentations. This feature is available to all subscribers to the journal.
You MUST read and follow the guidelines at Request to Reproduce AJR Content if you are distributing or using AJR content beyond academic use (limited distribution, non-revenue producing, or educational purposes).
(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
Fig. 1. —Schematic diagram of sequence of protocol used for our pilot study.
Patients were randomized (R) to neoadjuvant chemotherapy (CT), either
doxorubicin (ADR, Pharmacia Inc.) followed by paclitaxel (Taxol, Bristol-Myers
Squibb Company) or vice versa. Physical examination and imaging (i.e.,
mammography, breast sonography, and breast MRI) were performed. Each patient
received single-agent neoadjuvant chemotherapy; then physical examination and
imaging examinations were repeated. Second chemotherapeutic agent was given to
patient, and physical examination and imaging examinations were repeated.
Patient underwent surgery, either lumpectomy or mastectomy, and final
pathology results were obtained.
